Stephen Oh, MD, PhD

Closing out their discussion on myeloproliferative neoplasms, key opinion leaders share excitement for future evolutions in the treatment paradigm.

Following their overview on novel treatment modalities in myeloproliferative neoplasms, expert panelists consider how best to sequence and manage novel therapies in practice.

A broad and comprehensive review of novel targeted agents under investigation in the setting of myeloproliferative neoplasm management.

Key opinion leaders on myeloproliferative neoplasms review the potential of CALR as a therapeutic target following data from the ASH 2022 Annual Meeting.

Expert panelists consider the ongoing role of transplant for patients with myelofibrosis and discuss when it is more appropriate to explore systemic therapy options.

Closing out their discussion on the management of myelofibrosis, panelists highlight updated data with fedratinib and ruxolitinib, respectively.

A brief review of the biology of myelofibrosis, the potential for disease modification, and subsequent implications for treatment.

Key opinion leaders on myeloproliferative neoplasms review clinical data behind pacritinib therapy in the setting of myelofibrosis.

Switching their focus to myelofibrosis management, expert panelists reflect on clinical data behind momelotinib, a novel JAK2 inhibitor.

Stephen T. Oh, MD, PhD, discusses the anemia benefit of pacritinib in patients with myelofibrosis.

Shared insight on how a patient’s symptom burden can impact management strategies within essential thrombocytopenia and polycythemia vera.

Expert perspectives on the respective treatment landscapes of essential thrombocytopenia (ET) and polycythemia vera (PV) following the ASH 2022 Annual Meeting.

Dr Stephen Oh reviews the use of pacritinib in patients with myelofibrosis and the impact on anemia. Funding supported by CTI Biopharma. Content independently developed by OncLive.

Stephen T. Oh, MD, PhD, discusses the benefits of pacritinib in patients with myelofibrosis.

Dr Oh reviews data assessing the impact of pacritinib on anemia in patients from the PERSIST-2 trial. Funding supported by CTI BioPharma. Content independently developed by OncLive.

Closing out their discussion on myelofibrosis, experts provide practical advice for identifying and managing patients in real-world practice.

Focusing on novel combination strategies, experts review clinical trial data and consider where these regimens may fall in the myelofibrosis treatment armamentarium.

A comprehensive review of novel agents currently under investigation with a potential role in the myelofibrosis treatment landscape.

Expert perspectives on monitoring patients receiving therapy for myelofibrosis, with additional considerations for when it is appropriate to switch therapy.

Taking into account the three JAK inhibitors, ruxolitinib, fedratinib, and pacritinib, experts reflect on the appropriate use of each agent in myelofibrosis.

Shared insight on the respective roles of fedratinib and pacritinib in patients diagnosed with myelofibrosis.

Expert perspectives on the role of ruxolitinib in patients who require systemic therapy for myelofibrosis.

A brief review of the historical use of systemic therapy in patients who present with myelofibrosis.

Stephen Oh, MD, PhD, highlights the role of transplant in myelofibrosis before Ruben Mesa, MD, discusses factors in selecting systemic therapy.

Expert Pankit Vachhani, MD, breaks down best practices in observation and dictates when it is best to initiated therapy for myelofibrosis.

Experts focus on how best to risk stratify and stage myelofibrosis using appropriate diagnostic tools and workup.

Reflections on the predominant challenges one may face while making a differential diagnosis of myelofibrosis.

Shared insight on the differential diagnosis of myelofibrosis, including advice for identifying primary versus secondary disease.

A brief discussion on the role of ruxolitinib in the management of polycythemia vera, followed by a review of goals of therapy in this setting.

Pankit Vachhani, MD, provides a comprehensive overview of approved agents used to manage patients with polycythemia vera.